Potent β-Amyloid Modulators
Esther García‐Palomero(Universitat de Barcelona), Ana Martı́nez(Consejo Superior de Investigaciones Científicas), Celia de Austria(Universitat de Barcelona), Pierre Garcia(Centre Hospitalier de Luxembourg), Miguel Medina(Baptist Hospital of Miami), Patricia L. A. Muñoz-Muñoz(Neuron BioPharma (Spain)), Rita Valenzuela(Biomedical Research Networking Center on Neurodegenerative Diseases), Laura Rubio(Pontificia Universidad Católica Madre y Maestra), Paola Usán(Universitat de Barcelona), Elizabeth Delgado(Arizona State University)
Cited by 45
Related Papers
COVID-19: Drug Targets and Potential Treatments
|Journal of Medicinal Chemistry|2020|469
First Non-ATP Competitive Glycogen Synthase Kinase 3 β (GSK-3β) Inhibitors: Thiadiazolidinones (TDZD) as Potential Drugs for the Treatment of Alzheimer's Disease
|Journal of Medicinal Chemistry|2002|448
GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS
|Frontiers in Molecular Neuroscience|2011|348
Glycogen synthase kinase 3 (GSK‐3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation
|Medicinal Research Reviews|2002|334
Parkin Localizes to the Lewy Bodies of Parkinson Disease and Dementia with Lewy Bodies
|American Journal Of Pathology|2002|331